BeOne Medicines (ONC) Presents Updated BRUKINSA Phase 3 Data at EHA
Key takeaways
- Be One Medicines (ONC) Presents Updated BRUKINSA Phase 3 Data at EHA Abdul Rahman Sun, June 21, 2026 at 1:47 AM GMT+7 1 min read ONC Be One Medicines Ltd.
- The company markets BRUKINSA as a targeted prescription medication for the treatment of various types of B-cell blood cancers in adults.
- The study results showed sustained benefit from the use of the drug to treat chronic lymphocytic leukemia or small lymphocytic lymphoma.
Be One Medicines (ONC) Presents Updated BRUKINSA Phase 3 Data at EHA Abdul Rahman Sun, June 21, 2026 at 1:47 AM GMT+7 1 min read ONC Be One Medicines Ltd. (NASDAQ:ONC) is one of the high-growth large-cap stocks to invest in. On June 11, Be One Medicines Ltd. (NASDAQ:ONC) presented updated Phase 3 clinical data at the European Hematology Association Congress for its approved BTK inhibitor, BRUKINSA.
The company markets BRUKINSA as a targeted prescription medication for the treatment of various types of B-cell blood cancers in adults. The oral small molecule inhibitor of Bruton’s tyrosine kinase (BTK) is designed to deliver complete and sustained inhibition of the BTK protein. It is currently approved in 80 markets.
The study results showed sustained benefit from the use of the drug to treat chronic lymphocytic leukemia or small lymphocytic lymphoma. The 78-month SEQUOIA data showed progression-free survival of 71.8% with the drug, compared with 31% with bendamustine-rituximab. The safety profile in the Phase 3 trial was also consistent with previous studies. The study results reinforced BRUKINSA’s role as a foundational BTK inhibitor after nearly 6.5 years of follow-up.